World-first lung cancer vaccine trials launched across seven countries
Doctors have begun the first clinical trials for the mRNA lung cancer vaccine BNT116, targeting non-small cell lung cancer across seven countries, aiming to improve patient survival rates.
Read original article
Doctors have initiated the world's first clinical trials for an mRNA lung cancer vaccine, BNT116, developed by BioNTech, aimed at treating non-small cell lung cancer (NSCLC). This groundbreaking trial is being conducted across 34 research sites in seven countries, including the UK, US, Germany, Hungary, Poland, Spain, and Turkey. The first patient in the UK, Janusz Racz, received the vaccine at University College London hospital. The trial will enroll approximately 130 patients, ranging from early-stage to late-stage cancer, to assess the vaccine's effectiveness alongside immunotherapy. The mRNA vaccine works by training the immune system to recognize and attack cancer cells while sparing healthy cells, a significant advancement over traditional chemotherapy. Experts believe this approach could significantly improve survival rates for lung cancer patients, who currently face low survival odds, especially in advanced stages. The trial's lead oncologist, Prof. Siow Ming Lee, expressed optimism about the potential of mRNA technology in cancer treatment, hoping it will become a standard care option globally. The initiative is part of a broader effort to fast-track innovative cancer treatments through clinical trials, with support from the UK government.
- The world's first mRNA lung cancer vaccine trials have begun in seven countries.
- The vaccine, BNT116, targets non-small cell lung cancer and aims to enhance immune response.
- Approximately 130 patients will participate in the trial, which includes various stages of lung cancer.
- The trial is expected to improve survival rates for lung cancer patients significantly.
- The initiative reflects a growing trend towards innovative cancer treatments using mRNA technology.
Related
Combined Covid-flu vaccines are coming: Moderna jab clears major test
Moderna completes phase-III trials for a COVID-flu mRNA vaccine, showing higher efficacy in adults over 50. Plans for FDA approval highlight benefits of combination vaccines and mRNA technology's adaptability to variants.
Immunotherapy Is Changing Cancer Treatment Forever
Immunotherapy, especially in glioblastoma cases, has shown significant progress. Mass General researchers use genetically modified white blood cells to target tumors, leading to rapid regression. This innovative approach offers hope for challenging cancer cases.
World-first mRNA lung cancer vaccine trials launched in seven countries
Doctors have begun the first clinical trials for the mRNA lung cancer vaccine BNT116 in seven countries, targeting non-small cell lung cancer and aiming to improve patient survival rates.
Lung cancer vaccine trial begins in UK
A new lung cancer vaccine trial using mRNA technology has begun in the UK, involving 130 patients across seven countries. The BNT116 vaccine targets cancer cells, aiming to reduce side effects.
1 comments>> Lee said: “We hope adding this additional treatment will stop the cancer coming back because a lot of time for lung cancer patients, even after surgery and radiation, it does come back.”
>> He added: “I’ve been in lung cancer research for 40 years now. When I started in the 1990s, nobody believed chemotherapy worked.
>> “We now know about 20-30% [of patients] stay alive with stage 4 with immunotherapy and now we want to improve survival rates. So hopefully this mRNA vaccine, on top of immunotherapy, might provide the extra boost.
Related
Combined Covid-flu vaccines are coming: Moderna jab clears major test
Moderna completes phase-III trials for a COVID-flu mRNA vaccine, showing higher efficacy in adults over 50. Plans for FDA approval highlight benefits of combination vaccines and mRNA technology's adaptability to variants.
Immunotherapy Is Changing Cancer Treatment Forever
Immunotherapy, especially in glioblastoma cases, has shown significant progress. Mass General researchers use genetically modified white blood cells to target tumors, leading to rapid regression. This innovative approach offers hope for challenging cancer cases.
World-first mRNA lung cancer vaccine trials launched in seven countries
Doctors have begun the first clinical trials for the mRNA lung cancer vaccine BNT116 in seven countries, targeting non-small cell lung cancer and aiming to improve patient survival rates.
Lung cancer vaccine trial begins in UK
A new lung cancer vaccine trial using mRNA technology has begun in the UK, involving 130 patients across seven countries. The BNT116 vaccine targets cancer cells, aiming to reduce side effects.